Friday, July 10, 2026

pharma · Infertility in women undergoing assisted reproductive technologies (ART) · Intermediate risk, non-muscle invasive bladder cancer

Ferring Pharmaceuticals

Ferring Pharmaceuticals clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

-, St-Prex, 1162, CH, Mumbai HQ
1950 Founded
6,228 Employees
NMPA registrant Type
Company details
Status
Public
HQ
-, St-Prex, 1162, CH, Mumbai
Founded
1950
Employees
6,228
Programs
13
Drugs
23
Patents
0
Intelligence · Clinical Programs

Ferring Pharmaceuticals projects

13 ClinicalTrials.gov programs sponsored by Ferring Pharmaceuticals.

Ferring Pharmaceuticals has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 000434

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial
  2. ADSTILADRIN

    Ferring Pharmaceuticals

    Intermediate risk, non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial
  3. Desmopressin

    Ferring Pharmaceuticals

    Nocturia

    phase 3 small molecule completed

    1 trial
  4. FE 999326

    Ferring Pharmaceuticals

    Bladder Cancer

    phase 3 small molecule active

    1 trial
  5. FE 999913 vaginal tablet

    Ferring Pharmaceuticals

    Luteal Hormone Supplementation

    phase 3 small molecule completed

    1 trial
  6. Follitropin alfa

    Ferring Pharmaceuticals

    Controlled Ovarian Simulation

    phase 3 small molecule completed

    1 trial
  7. ADSTILADRIN

    Ferring Pharmaceuticals

    Low-grade upper track urothelial carcinoma (LG-UTUC)

    phase 2 small molecule active

    1 trial
  8. REKOVELLE for Idiopathic male infertility (in…

    Ferring Pharmaceuticals

    Idiopathic male infertility (including oligoasthenozoospermia).

    phase 2 small molecule active

    1 trial
  9. TRI-001-01

    Ferring Pharmaceuticals

    Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)

    phase 2 small molecule active

    1 trial
  10. 000414

    Ferring Pharmaceuticals

    Inflammatory Gastrointestinal Disease

    phase 1 other active

    1 trial
  11. 000426

    Ferring Pharmaceuticals

    Infertility in women undergoing assisted reproductive technologies (ART)

    phase 1 other active

    1 trial
  12. 000427

    Ferring Pharmaceuticals

    Infertility in women undergoing assisted reproductive technologies (ART)

    phase 1 other active

    1 trial
  13. Budesonide

    Ferring Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Ferring Pharmaceuticals have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.